# Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women

> **NCT03564613** · — · RECRUITING · sponsor: **ViiV Healthcare** · enrollment: 250 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** DTG

## Key facts

- **NCT ID:** NCT03564613
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2019-11-18
- **Primary completion:** 2024-10-30
- **Final completion:** 2024-10-30
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2024-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03564613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03564613, "Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03564613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*